Herceptin Should Be Used With Caution In Pulmonary Compromised Patients
Executive Summary
Genentech is revising Herceptin labeling to add warnings about fatal hypersensitivity, infusion and pulmonary reactions in breast cancer patients being treated with the anti-HER2 oncologic.
You may also be interested in...
Herceptin Serious Infusion-Related AEs Hold At .25% Of Patients - Genentech
The reporting rate for serious infusion-related adverse events for Genentech's breast cancer agent Herceptin (trastuzumab) has not changed from the .25% of treated patients reported in May, the company indicated after issuing a "Dear Doctor" letter Oct. 6 notifying healthcare professionals of updates to warnings in labeling.
Herceptin Serious Infusion-Related AEs Hold At .25% Of Patients - Genentech
The reporting rate for serious infusion-related adverse events for Genentech's breast cancer agent Herceptin (trastuzumab) has not changed from the .25% of treated patients reported in May, the company indicated after issuing a "Dear Doctor" letter Oct. 6 notifying healthcare professionals of updates to warnings in labeling.
Genentech Herceptin
Label will be revised to stress precautions that the breast cancer therapy Herceptin (trastuzumab) be reconstituted with 20 mL of bacteriostatic water for injection as a diluent and that it be handled with caution during reconstitution. Genentech advised healthcare providers of the changes in a recent letter